Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
1408  

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

September 25, 2018
News  
GNP+ Announces Search for Executive Director
1294  

GNP+ Announces Search for Executive Director

The Global Network of People Living with HIV (GNP+) is searching for a skilled and passionate leader and manager to lead its organization in the implementation of an exciting and ambitious strategic plan.

September 18, 2018
News  
Global Fund Partnership has Saved 27 Million Lives
1022  

Global Fund Partnership has Saved 27 Million Lives

The Global Fund to Fight AIDS, Tuberculosis and Malaria released a report today demonstrating that 27 million lives have been saved by the Global Fund partnership. The report shows tremendous progress that has been achieved by efforts to end the epidemics, while highlighting new threats.

September 14, 2018
News